References
[1] J. E. Hawkes, T. C. Chan and J. G. Krueger: Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol, 140(3) (2017) 645-653, doi:10.1016/j.jaci.2017.07.004.
[2] A. W. Armstrong and C. Read: Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. Jama, 323 (19) (2020) 1945-1960, doi:10.1001/jama.2020.4006.
[3] K. Ghoreschi, A. Balato, C. Enerbäck and R. Sabat: Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet, 397 (10275) (2021) 754-766, doi:10.1016/s0140-6736(21)00184-7.
[4] L. Pasquali, A. Srivastava, F. Meisgen, K. Das Mahapatra, P. Xia, N. Xu Landén, A. Pivarcsi and E. Sonkoly: The Keratinocyte Transcriptome in Psoriasis: Pathways Related to Immune Responses, Cell Cycle and Keratinization. Acta Derm Venereol, 99 (2) (2019) 196-205, doi:10.2340/00015555-3066.
[5] B. W. Kirkham, A. Kavanaugh and K. Reich: Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology, 141 (2) (2014) 133-42, doi:10.1111/imm.12142.
[6] A. Blauvelt and A. Chiricozzi: The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol, 55 (3) (2018) 379-390, doi:10.1007/s12016-018-8702-3.
[7] D. A. Martin, J. E. Towne, G. Kricorian, P. Klekotka, J. E. Gudjonsson, J. G. Krueger and C. B. Russell: The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol, 133 (1) (2013) 17-26, doi:10.1038/jid.2012.194.
[8] C. Christmann, S. Zenker, L. Martens, J. Hübner, K. Loser, T. Vogl and J. Roth: Interleukin 17 Promotes Expression of Alarmins S100A8 and S100A9 During the Inflammatory Response of Keratinocytes. Front Immunol, 11, (2020) 599947, doi:10.3389/fimmu.2020.599947.
[9] H. Zhao, L. Wu, G. Yan, Y. Chen, M. Zhou, Y. Wu and Y. Li: Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther, 6 (1) (2021) 263, doi:10.1038/s41392-021-00658-5.
[10] Z. Wang, H. Zhou, H. Zheng and X. Zhou: Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation, 17 (2) (2021) 529-552, doi:10.1080/15548627.2020.1725381.
[11] C. Zhang, C. Xiao, E. Dang, J. Cao, Z. Zhu, M. Fu, X. Yao, Y. Liu, B. Jin, G. Wang and W. Li: CD100-Plexin-B2 Promotes the Inflammation in Psoriasis by Activating NF-κB and the Inflammasome in Keratinocytes. J Invest Dermatol, 138 (2) (2018) 375-383, doi:10.1016/j.jid.2017.09.005.
[12] R. Matsumoto, T. Dainichi, S. Tsuchiya, T. Nomura, A. Kitoh, M. S. Hayden, K. J. Ishii, M. Tanaka, T. Honda, G. Egawa, A. Otsuka, S. Nakajima, K. Sakurai, Y. Nakano, T. Kobayashi, Y. Sugimoto and K. Kabashima: Epithelial TRAF6 drives IL-17-mediated psoriatic inflammation. JCI Insight, 3 (15) (2018) e121175, doi:10.1172/jci.insight.121175.
[13] E. G. Harper, C. Guo, H. Rizzo, J. V. Lillis, S. E. Kurtz, I. Skorcheva, D. Purdy, E. Fitch, M. Iordanov and A. Blauvelt: Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol, 129 (9) (2009) 2175-83, doi:10.1038/jid.2009.65.
[14] C. Q. F. Wang, Y. T. Akalu, M. Suarez-Farinas, J. Gonzalez, H. Mitsui, M. A. Lowes, S. J. Orlow, P. Manga and J. G. Krueger: IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol, 133 (12) (2013) 2741-2752, doi:10.1038/jid.2013.237.
[15] J. Kim and J. G. Krueger: Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. Annu Rev Med, 68 (2017) 255-269, doi:10.1146/annurev-med-042915-103905.
[16] Z. M. Zhang, N. Zhong, H. Q. Gao, S. Z. Zhang, Y. Wei, H. Xin, X. Mei, H. S. Hou, X. Y. Lin and Q. Shi: Inducing apoptosis and upregulation of Bax and Fas ligand expression by allicin in hepatocellular carcinoma in Balb/c nude mice. Chin Med J (Engl), 119 (5) (2006) 422-425, 10.1001/jama.295.10.1172.
[17] L. Wang, H. Jiao, J. Zhao, X. Wang, S. Sun and H. Lin: Allicin Alleviates Reticuloendotheliosis Virus-Induced Immunosuppression via ERK/Mitogen-Activated Protein Kinase Pathway in Specific Pathogen-Free Chickens. Front Immunol, 8 (2017) 1856, doi:10.3389/fimmu.2017.01856.
[18] M. Sarvizadeh, O. Hasanpour, Z. Naderi Ghale-Noie, S. Mollazadeh, M. Rezaei, H. Pourghadamyari, M. Masoud Khooy, M. Aschner, H. Khan, N. Rezaei, L. Shojaie and H. Mirzaei: Allicin and Digestive System Cancers: From Chemical Structure to Its Therapeutic Opportunities. Front Oncol, 11 (2021) 650256, doi:10.3389/fonc.2021.650256.
[19] N. Caporaso, S. M. Smith and R. H. Eng: Antifungal activity in human urine and serum after ingestion of garlic (Allium sativum). Antimicrob Agents Chemother, 23 (5) (1983) 700-2, doi:10.1128/aac.23.5.700.
[20] J. Borlinghaus, F. Albrecht, M. C. Gruhlke, I. D. Nwachukwu and A. J. Slusarenko: Allicin: chemistry and biological properties. Molecules, 19 (8) (2014) 12591-618, doi:10.3390/molecules190812591.
[21] P. Rose, P. K. Moore, M. Whiteman and Y. Z. Zhu: An Appraisal of Developments in Allium Sulfur Chemistry: Expanding the Pharmacopeia of Garlic. Molecules, 24(21) (2019) 4006, doi:10.3390/molecules24214006.
[22] X. Li and J. Chen: Method for preparing of Allicin injection and low-temperature continuous stirring ultrafiltration device thereof, United States Patent, 2015 US, 9023623B2.
[23] K. E. Nograles, L. C. Zaba, E. Guttman-Yassky, J. Fuentes-Duculan, M. Suárez-Fariñas, I. Cardinale, A. Khatcherian, J. Gonzalez, K. C. Pierson, T. R. White, C. Pensabene, I. Coats, I. Novitskaya, M. A. Lowes and J. G. Krueger: Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol, 159 (5) (2008) 1092-102, doi:10.1111/j.1365-2133.2008.08769.x.
[24] T. P. Singh, C. H. Lee and J. M. Farber: Chemokine receptors in psoriasis. Expert Opin Ther Targets, 17 (12) (2013) 1405-22, doi:10.1517/14728222.2013.838220.
[25] H. He, R. Bissonnette, J. Wu, A. Diaz, E. Saint-Cyr Proulx, C. Maari, C. Jack, M. Louis, Y. Estrada, J. G. Krueger, N. Zhang, A. B. Pavel and E. Guttman-Yassky: Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy Clin Immunol, 147 (1) (2021) 199-212, doi:10.1016/j.jaci.2020.05.048.
[26] M. Furue, K. Furue, G. Tsuji and T. Nakahara: Interleukin-17A and Keratinocytes in Psoriasis. Int J Mol Sci, 21 (4) (2020) 1275, doi:10.3390/ijms21041275.
[27] S. Wang, R. Song, Z. Wang, Z. Jing, S. Wang and J. Ma: S100A8/A9 in Inflammation. Front Immunol, 9 (2018) 1298, doi:10.3389/fimmu.2018.01298.
[28] T. Kobayashi, P. T. Walsh, M. C. Walsh, K. M. Speirs, E. Chiffoleau, C. G. King, W. W. Hancock, J. H. Caamano, C. A. Hunter, P. Scott, L. A. Turka and Y. Choi: TRAF6 is a critical factor for dendritic cell maturation and development. Immunity, 19(3) (2003)353-63, doi:10.1016/s1074-7613(03)00230-9.
[29] Y. Jiang, L. C. Tsoi, A. C. Billi, N. L. Ward, P. W. Harms, C. Zeng, E. Maverakis, J. M. Kahlenberg and J. E. Gudjonsson: Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin. JCI Insight, 5(20) (2020) e142067, doi:10.1172/jci.insight.142067.
[30] Y. A. Elnabawi, M. S. Garshick, M. Tawil, T. J. Barrett, E. A. Fisher, K. Lo Sicco, A. L. Neimann, J. U. Scher, J. Krueger and J. S. Berger: CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. J Am Acad Dermatol, 84 (4) (2021) 913-920, doi:10.1016/j.jaad.2020.10.094.
[31] J. Austermann, S. Zenker and J. Roth: S100-alarmins: potential therapeutic targets for arthritis. Expert Opin Ther Targets, 21 (7) (2017)739-751, doi:10.1080/14728222.2017.1330411.
[32] H. B. Schonthaler, J. Guinea-Viniegra, S. K. Wculek, I. Ruppen, P. Ximénez-Embún, A. Guío-Carrión, R. Navarro, N. Hogg, K. Ashman and E. F. Wagner: S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. Immunity, 39 (6) (2013) 1171-81, doi:10.1016/j.immuni.2013.11.011.
[33] S. Benoit, A. Toksoy, M. Ahlmann, M. Schmidt, C. Sunderkötter, D. Foell, M. Pasparakis, J. Roth and M. Goebeler: Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol, 155 (1) (2006) 62-6, doi:10.1111/j.1365-2133.2006.07198.x.
[34] N. Freise, A. Burghard and T. Ortkras: Signaling mechanisms inducing hyporesponsiveness of phagocytes during systemic inflammation, 134 (2) (2019) 134-146, doi:10.1182/blood.2019000320.
[35] A. K. Dey, A. A. Joshi, A. Chaturvedi, J. B. Lerman, T. M. Aberra, J. A. Rodante, H. L. Teague, C. L. Harrington, J. P. Rivers, J. H. Chung, M. T. Kabbany, B. Natarajan, J. I. Silverman, Q. Ng, G. E. Sanda, A. V. Sorokin, Y. Baumer, E. Gerson, R. B. Prussick, A. Ehrlich, L. J. Green, B. N. Lockshin, M. A. Ahlman, M. P. Playford, J. M. Gelfand and N. N. Mehta: Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. JAMA Cardiology, 2 (9) (2017) 1013-1018, doi:10.1001/jamacardio.2017.1213.
[36] C. L. Li, X. H. Liu, Y. Qiao, L. N. Ning, W. J. Li, Y. S. Sun, D. S. Liu, W. Gao and C. M. Ma: Allicin alleviates inflammation of diabetic macroangiopathy via the Nrf2 and NF-kB pathway. Eur J Pharmacol, 876 (2020) 173052, doi:10.1016/j.ejphar.2020.173052.
[37] L. Shi, Q. Lin, X. Li, Y. Nie, S. Sun, X. Deng, L. Wang, J. Lu, Y. Tang and F. Luo: Alliin, a garlic organosulfur compound, ameliorates gut inflammation through MAPK-NF-κB/AP-1/STAT-1 inactivation and PPAR-γ activation. Mol Nutr Food Res, 61 (9) (2017) doi:10.1002/mnfr.201601013.